Cannabinoids Reduce Extracellular Vesicle Release from HIV-1 Infected Myeloid Cells and Inhibit Viral Transcription
Authors:
- Catherine DeMarinoCDCatherine DeMarino
- Maria CowenMCMaria Cowen
- Pooja KhatkarPKPooja Khatkar
- Bianca CottoBCBianca Cotto
- Heather BranscomeHeather Branscome
- Yuriy KimYKYuriy Kim
- Sarah Al SharifSSSarah Al Sharif
- Emmanuel T. AgbottahEAEmmanuel T. Agbottah
- Weidong ZhouWZWeidong Zhou
- Cecilia T. CostiniukCCCecilia T. Costiniuk
- Mohammad-Ali JenabianMJMohammad-Ali Jenabian
- Cohava GelberCGCohava Gelber
Open Access
Abstract
Of the 37.9 million individuals infected with human immunodeficiency virus type 1 (HIV-1), approximately 50% exhibit HIV-associated neurocognitive disorders (HAND). We and others previously showed that HIV-1 viral RNAs, such as trans-activating response (TAR) RNA, are incorporated into extracellular vesicles (EVs) and elicit an inflammatory response in recipient naïve cells. Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC), the primary cannabinoids present in cannabis, are effective in reducing inflammation. Studies show that cannabis use in people living with HIV-1 is associated with lower viral load, lower circulating CD16+ monocytes and high CD4+ T-cell counts, suggesting a potentially therapeutic application. Here, HIV-1 infected U1 monocytes and primary macrophages were used to assess the effects of CBD. Post-CBD treatment, EV concentrations were analyzed using nanoparticle tracking analysis. Changes in intracellular and EV-associated viral RNA were quantified using RT-qPCR, and changes in viral proteins, EV markers, and autophagy proteins were assessed by Western blot. Our data suggest that CBD significantly reduces the number of EVs released from infected cells and that this may be mediated by reducing viral transcription and autophagy activation. Therefore, CBD may exert a protective effect by alleviating the pathogenic effects of EVs in HIV-1 and CNS-related infections.Keywords
Funding Information
- National Institute of Health, United States (AI078859, AI074410, AI127351-01, AI043894, NS099029)
- National Institute of Health, United States (DA050176)
- National Institute of Health (R33CA206937, R01AR068436, F31NS109443)
- Targeted Pharmaceuticals (GMU#223390)
- Québec research funding body (FRQ-S Junior 1 clinician-researcher salary award)
This publication has 126 references indexed in Scilit:
- Microarray and Pathway Analysis Reveal Distinct Mechanisms Underlying Cannabinoid-Mediated Modulation of LPS-Induced Activation of BV-2 Microglial CellsPLOS ONE, 2013
- Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9‐tetrahydrocannabinol in BV‐2 microglial cellsBritish Journal of Pharmacology, 2012
- Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced microglia neurotoxicityCell Death & Disease, 2012
- Cannabidiol Reduces Aβ-Induced Neuroinflammation and Promotes Hippocampal Neurogenesis through PPARγ InvolvementPLOS ONE, 2011
- The Human Immunodeficiency Virus Coat Protein gp120 Promotes Forward Trafficking and Surface Clustering of NMDA Receptors in Membrane MicrodomainsJournal of Neuroscience, 2011
- The ESCRT PathwayDevelopmental Cell, 2011
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2Pharmacological Reviews, 2010
- N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptorBMC Neuroscience, 2010
- Association of FAK activation with lentivirus-induced disruption of blood-brain barrier tight junction–associated ZO-1 protein organizationJournal of NeuroVirology, 2009
- Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppressionProceedings of the National Academy of Sciences, 2006